Publications

“Circumventing Polysorbate Induced Unwanted Immunogenicity and Anaphylaxis,” Maggio ET, Journal of Bioequivalence & Bioavailability” J Bioequiv Availab (2017), 9:499-500. DOI: 0.4172/jbb.1000352
“Reducing or Eliminating Polysorbate Induced Anaphylaxis and Unwanted Immunogenicity in Biotherapeutics” Maggio ET, J. Excipients and Food Chem (2017) 8 (3): 52 -61
“Polysorbates, Biotherapeutics, and Anaphylaxis: A Review” Maggio ET, BioProcess International (2017) 15(8): 48-52
“Alkyl Mono- and Diglucosides: Highly Effective, Nonionic Surfactant Replacements for Polysorbates in Biotherapeutics — a Review” Maggio ET, BioProcess International (2016)14(3): 30-49
“Novel Excipients Prevent Aggregation in Manufacturing and Formulation of Protein and Peptide Therapeutics” Maggio ET, Best of Bioprocess International (2014): Podcast
“Unwanted Immunogenicity: From Risk Assessment to Risk Management” Cheryl Scott, BioProcess International (2014) 12(10): 2-16
“Absorption enhancing excipients in nasal drug delivery”, Maggio ET, J. Excipients and Food Chem. (2014) 5(2): 100-112
“FORMULATING PEPTIDES – Novel Formulations for Non-Invasive Delivery & Stabilization of Peptides”, Maggio, ET, Drug Development and Delivery (2013) 33(8): 68-75. – Available online at: http://www.drug-dev.com/Main/Back-Issues/FORMULATING-PEPTIDES-Novel-Formulations-for-NonInv-631.aspx
“Biosimilars, Oxidative Damage, and Unwanted Immunogenicity”, ET Maggio, , BioProcess International, Vol. 11, No. S6, June 2013, pp. 28-34 – Full PDF available online at: http://www.bioprocessintl.com
PDF “Polysorbates, peroxides, protein aggregation, and immunogenicity – a growing concern” Maggio ET, J. Excipients and Food Chem. (2012) 3(2): 45-53
PDF “Use of excipients to control aggregation in peptide and protein formulations.”, Maggio ET, J. Excipients and Food Chem. (2010) 1(2): 40-49
PDF “Highly Bioavailable Nasal Calcitonin – Potential for Expanded Use in Analgesia”. Maggio ET, Meezan E, Ghambeer DKS and Pillion DJ, Drug Delivery Technology (2010) 10(1): 58-63.
“Noninvasive Delivery Offers Opportunities For Large And Small Pharma” in Life Science Leader Maggio ET, January 2010 issue, p.45
“Polysorbates, Immunogenicity, and the Totality of the Evidence”, Maggio ET, BioProcess International, (2012) 10(10): 44–49 Full PDF available online at: http://www.bioprocessintl.com
“High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers”, Maggio ET & Pillion DJ, Drug Deliv. and Transl. Res.(2013) 3:16-25, abstract only – Full PDF available online at: http://rd.springer.com/article/10.1007/s13346-012-0069-z
“Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice”, Maggio ET, Grasso P, Regulatory Peptides (2011) 167: 233–238
“n-Dodecyl-β-D-Maltoside Inhibits Aggregation of Human Interferon-β-1b and Reduces Its Immunogenicity”, Rifkin RA, Maggio ET, Dike S, Kerr DA and Levy M, J Neuroimmune Pharmacol (2010) 6(1): 158-162
“Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels”, Novakovic ZM, Leinung MC, Lee DW & Grasso P, Diabetes, Obesity and  Metabolism (2010) 12(6):532-539
“Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: A study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration”. Lee DW, Leinung MC and Grasso P, Regulatory Peptides (2010) 160: 129–132
PDF “Intranasal (IN) Pharmacokinetics (PK) and Bioavailability of ZT-031, a Novel Parathyroid Hormone (PTH) Analog”, Eddy P, Krause D, Merutka G and MacDonald B, Presented at the ASBMR 30th Annual Meeting Sept. 16, 2009.
PDF “Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems” (Abstract), Novakovic ZM, Leinung MC, Lee DW, and Grasso P, Regulatory Peptides (2009) 154:107-111
PDF “Novel Excipients Prevent Aggregation in Manufacturing and Formulation of Protein and Peptide Therapeutics” in BioProcess International – (2008), 58-65.
PDF “Non-Invasive Peptide Delivery, Reformulation, and the Pharma Finance Environment” in PharmaVentures’ Drug Delivery Report – Winter 2007/2008
PDF “Intravail®: Highly Effective Intranasal Delivery Of Peptide And Protein Drugs” – Expert Opin. Drug Deliv. (2006) 3(4):529-539